S. Trager-Maury

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

[Use of complementary medicine by cancer patients in a French oncology department].

S. Trager-Maury, Christophe Tournigand, Pauline Afchain et al. · PubMed · 2007 · 58 citations

Medicine, Oncology, Pharmacotherapy +9

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

F. Joly, Djihane Ahmed-Lecheheb, Elsa Kalbacher et al. · Annals of Oncology · 2019 · 55 citations

Medicine, Gynecology, Oncology +10

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Olivier Trédan, Philippe Follana, Isabelle Moullet et al. · Annals of Oncology · 2016 · 26 citations · Full text

Medicine, Oncology, Pharmacology +11